Phaseline

Companies › Cerenome

Cerenome: clinical trials, targets and expected readouts

1 active drug program in 5 registered trials: 5 Phase 1; Oncology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Rhenium-186 Nanoliposome (186RNL)
186Re-BMEDA-chelated radionuclide encapsulated in liposomes for convection-enhanced delive
–Phase 1Leptomeningeal Metastasis; Glioma; EpendymomaApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05034497Rhenium-186 Nanoliposome (186RNL)Phase 1Leptomeningeal MetastasisOncologyOct 2026
NCT01906385Rhenium-186 Nanoliposome (186RNL)Phase 1GliomaOncologyApr 2027
NCT07098806Rhenium-186 Nanoliposome (186RNL)Phase 1Leptomeningeal MetastasisOncologyJul 2027
NCT05460507Rhenium-186 Nanoliposome (186RNL)Phase 1GliomaOncologyMar 2028
NCT07061626Rhenium-186 Nanoliposome (186RNL)Phase 1EpendymomaOncologyMar 2028

From the company's SEC filings

Cash and short-term investments of $9m on 2026-06-30; operating cash outflow about $27m a year; runway about 4 months at that burn, to Oct 2026

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.